Merck to present oncology data across 25 cancer types at ASCO 2026

Merck (NYSE: MRK) announced it will present research from more than 100 abstracts across over 25 types of cancer at the 2026 American Society of Clinical Oncology Annual Meeting from May 29-June 2.

The pharmaceutical company will showcase five-year follow-up data from the KEYNOTE-942 trial evaluating intismeran autogene in combination with KEYTRUDA for patients with high-risk melanoma following complete resection. The study represents continued research into individualized neoantigen therapy approaches.

Final analysis results from the KEYNOTE-522 trial will demonstrate survival benefits for patients with high-risk early-stage triple-negative breast cancer treated with KEYTRUDA in combination with chemotherapy as pre-operative treatment, followed by single-agent continuation after surgery.

New data for sacituzumab tirumotecan, an investigational TROP2-directed antibody-drug conjugate, will add to research of treatment approaches for patients with non-small cell lung cancer. The Phase 3 OptiTROP-Lung05 trial conducted in China by Kelun-Biotech evaluated the drug plus KEYTRUDA in advanced non-small cell lung cancer.

Progression-free survival data from the ASCENT-04/KEYNOTE-D19 study evaluating KEYTRUDA plus Trodelvy for patients with metastatic triple-negative breast cancer will be featured in the official ASCO Press Program.

Additional presentations will include six-year follow-up data from KEYNOTE-811 evaluating KEYTRUDA plus trastuzumab and chemotherapy for HER2-positive gastric cancer, and extended follow-up from the LITESPARK-004 study of belzutifan in patients with von Hippel-Lindau disease-associated neoplasms.

Merck will hold an oncology investor event on June 1, 2026, during the ASCO meeting to provide updates on the company's oncology strategy and program.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• A.O. Smith executive chairman to retire, CEO to assume chairman role
• Gil Issachar steps down as CTO at Firefly Neuroscience